ABSTRACT
Introduction

Acquired
Amegakaryocytic Thrombocytopenic Purpura (AATP) is a rare cause of thrombocytopenia associated with decreased or absent megakaryocytes in otherwise normal bone marrow.
[1] The incidence and prevalence of this disease is unknown as most of the cases are under diagnosed or misdiagnosed as immune thrombocytopenia (ITP) since it is the most common cause of thrombocytopenia in this age group. Herein, we present a case of AATP in a three year old female child which was first treated as immune thrombocytopenia and later diagnosed and treated for AATP.
Case Report
A three year old female presented with history of fever on and off since one week, bleeding from nose and redness of eyes since four days. On examination she had multiple petechiae all over the body and sub conjunctival hemorrhage. Per abdomen was normal without organomegaly. A complete blood count (CBC) and a peripheral smear examination were done as a routine investigation. CBC showed Hemoglobin-10.6 gm%, Total leucocyte count-15,500, total platelet count-7,000. The child was given platelet transfusion and a repeat CBC was done which showed an increase in the platelet count. But, platelet count starts falling after every 3-4 days of platelet transfusion. The child was then planned to be treated with Anti Thymocyte Globulin (ATG) 15mg/Kg/day and showed a very good response with it. Further, the patient was advised for stem cell transplantation for permanent cure and also regular follow up was advised.
Discussion
The pathophysiology of AATP is uncertain. It may be a primary disorder or may be seen in aplastic anemia (AA), pre leukemia, Myelodysplastic Syndrome (MDS) secondary to exposure to environmental agents such as viruses (Cytomegalovirus, Parvovirus B19) and certain toxins such as benzene.
[2] Both humoral and cell mediated immune suppression of megakaryocytopoiesis have been linked to the pathogenesis of this unusual disorder. Hoffman et al. suggested that the defect in AATP occurred in an early progenitor cell of themegakaryocytic lineage.
[3] Gewirtz et al. in 1986 proposed cell mediated suppression of megakaryocytopoiesis by demonstrating in vitro suppression of megakaryocyte colony formation by autologous ancillary marrow cells in two cases of AATP. [4] Shiozaki et al. further elaborated on the role of humoral antibodies in 2000,when they reported a case of AATP with high levels of antithrombopoietin (TPO) IgG antibodies. [5] Cytogenetic abnormalities have been shown to occur in association with AATP however, their precise role is not understood. [6] This disorder has to be differentiated from Congenital Amegakarocytic Thrombocytopenic Purpura (CATP) which also presents with thrombocytopenia and absence of megakaryocytes in the bone marrow but this usually presents in the first day of life or usually within 1 month of age. [7] While some patients of AATP remain clinically stable, others may progress to aplastic anemia or pre leukemia in due course, [8] particularly if they present in very young age like in our case. So, careful follow up is needed. Standard treatment guidelines have not been established for AAT. The drugs that can be used for treatment are corticosteroids, lithium carbonate, androgens, vincristine, immunosuppressive drugs, platelet transfusions and plasma substitution. There have been sporadic reports of use of fresh frozen plasma FFP) and lithium carbonate in some of these patients. [8] [9] The inducing effect of FFP on thrombopoietin production, probably due to the presence of a thrombopoietin activator or derepressor may be responsible for the beneficial effect. [9] In occasional patients with subsequent platelet alloimmunization, splenectomy can be effective in reducing transfusion requirement and in maintaining long term clinical remission but that is not the choice in young age like our case. Antithymocyte globulin (ATG) alone, and cyclosporine alone or in combination with ATG, has been shown to be effective in treatment of AATP.
[10] But, there is the risk of further alloimmunization during the time of treatment with ATG.
[11] So, allogeneic bone marrow transplantation would seem to be the next step for a permanent cure, if a suitable matched sibling bone marrow donor can be identified and the patient can tolerate transplant.
[11]
Recently, mycophenolate mofetil was used to treat a single case of acquired megakaryocytic aplasia.
[12]
Conclusion
